MDMA announced the leadership change today, following the Washington, D.C.–based industry association’s annual meeting last week.
“Medical technology innovators are at the forefront of improving patient outcomes and reducing the cost of care, and I am honored to lead MDMA as they continue their tremendous work as the leading voice of our industry,” Trigg said in a news release. “Modern technology is impacting when, where and how healthcare can be delivered. Together, we have the privilege of imagining what the future of healthcare could look like, and turning invention into reality.”
Trigg succeeds Avalign Technologies CEO Jeff McCaulley, who held the role for three years and oversaw Medical Device User Fee Amendments (MDUFA) V negotiations and repeal of the medical device tax.
MDMA President and CEO Mark Leahey called Trigg “an amazing leader whose vision will help guide MDMA and our industry over the challenges and opportunities facing the delivery of healthcare in the 21st century.”
Trigg identified implementation of the MDUFA V agreement and shortening the gap between the regulatory process and securing reimbursement as some of the board’s top priorities in the coming years under her leadership.